about
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useAssociation between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic reviewDeterminants of U.S. Prescription Drug Utilization using County Level Data.Cost-analysis of the WHO Essential Medicines List in A Resource-Limited Setting: Experience from A District Hospital in India.Biosimilars: Implications for health-system pharmacists.Generic drugs: Review and experiences from South India.Accuracy of annual prescription drug expenditure forecasts in AJHPThe impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.Improving viable low cost generic medication prescription rate in primary care pediatric practice.Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.Biosimilars: part 2: potential concerns and challenges for p&t committees.A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs.The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.Trends and issues in oncology costs.What is a new drug worth? An innovative model for performance-based pricing.Spending on Hepatitis C Antivirals in the United States, 2009-2015.Projecting expenditure on medicines in the UK NHS.Biosimilars: part 1: proposed regulatory criteria for FDA approval.Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010-2015.High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
P2860
Q26863707-986E2DB6-81DB-4096-872A-CBBD5E755C3AQ27007695-0CF9CC8D-5A03-476F-A035-4693EA23447EQ28541457-9E74794D-B22F-41D8-ACFA-6653944EE947Q30938662-B4813944-0C02-4F49-A574-6E4A219498A3Q33839621-9C326C33-B721-42A6-B777-226434711CE6Q34372394-AC1CF34A-57C5-47E6-B9F9-F116B8F3F93BQ35948976-8FEB3704-2FDD-41FB-8570-B2BA072B1EFCQ36076762-C5705186-C2A4-44C8-9ECC-42449BD760F3Q36115981-BCE00B31-E921-4764-8E46-8437D3975D25Q36164727-727A0C5B-4BB8-45A3-8A1D-F1DDF17530AFQ36339862-B07D04B8-AE16-42BC-86BC-E6229383D711Q36409306-B0E19618-1CBF-4DF7-8E23-602BAD273C8FQ36678132-12F80954-DFCC-47F4-A9F8-C613802D6438Q37081551-FBCF0E07-A0BC-426A-AB12-316C487345CFQ38035419-E6D91821-076B-441D-B450-AA4275A0036EQ38109104-36565B5B-0714-4166-8596-19B37ED0CB23Q38170426-EA35401B-4EA0-4DA2-84FA-8E696F98B282Q38254384-F44ACF5C-41C2-4575-ABEA-3A2EE494A189Q39177479-07CE1F41-E4A8-439F-922D-6B8E3F6B1DACQ39350064-2BEBB54B-C8CE-44B4-9C9A-41C3BA3BBF24Q42545996-9D41FEFF-A708-440D-A83B-14387ED8424FQ47742725-E4C5170B-A9DE-4C81-9789-3EBD23298B10Q53206717-9EB97748-913C-45EC-A5A2-31E8DAD47FA9Q55231464-DA8BC7BF-3E2C-4C05-BCB7-19BEE2F38FF3
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Projecting future drug expenditures--2012.
@en
Projecting future drug expenditures--2012.
@nl
type
label
Projecting future drug expenditures--2012.
@en
Projecting future drug expenditures--2012.
@nl
prefLabel
Projecting future drug expenditures--2012.
@en
Projecting future drug expenditures--2012.
@nl
P2093
P356
P1476
Projecting future drug expenditures--2012.
@en
P2093
Fred Doloresco
Glen T Schumock
James M Hoffman
Lee C Vermeulen
Linda Matusiak
Nilay D Shah
Robert J Hunkler
P304
P356
10.2146/AJHP110697
P577
2012-03-01T00:00:00Z